ESR1 and breast cancer: In addition to the current study suggesting that RNA-sequencing can provide benchmarked intrinsic subtype and ROR scores, RNA-sequencing has also been reported to be able to provide reliable models for current conventional BC biomarkers29,32,33 and to identify expressed somatic mutations in for example ESR1 and PIK3CA43,44 that may be important for future clinical management.